Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect of these agents remain unclear. METHODS: H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yuchao, Tang, Lizhi, Zhang, Fang, Yan, Zhe, Li, Jing, Tong, Nanwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933032/
https://www.ncbi.nlm.nih.gov/pubmed/29849624
http://dx.doi.org/10.1155/2018/8457538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933032/
https://www.ncbi.nlm.nih.gov/pubmed/29849624
http://dx.doi.org/10.1155/2018/8457538

Ejemplares similares